Avidity biosciences announces inducement grants under nasdaq listing rule 5635(c)(4)

San diego , aug. 5, 2024 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced that on august 1, 2024, the human capital management committee of avidity's board of directors granted a non-qualified stock option award to purchase an aggregate of 160,000 shares of its common stock and 25,000 restricted stock units ("rsus") to john b. moriarty, jr., under the avidity biosciences, inc. 2022 employment inducement incentive award plan (the "2022 inducement plan"), in connection with mr.
RNA Ratings Summary
RNA Quant Ranking